Immunotherapeutic GSK2132231A

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Melanoma

Phase 2

A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients

TerminatedNCT00849875

GlaxoSmithKlineMelanoma

Start: 2009-05-26End: 2014-11-17Updated: 2017-07-12

Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma

CompletedNCT00896480

GlaxoSmithKlineMelanoma

Start: 2009-05-19End: 2014-11-03Updated: 2021-04-08

A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma

CompletedNCT00942162

GlaxoSmithKlineMelanoma

Start: 2009-08-14End: 2015-04-01Updated: 2020-12-08

Related Papers

Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic.

2018-07-251 citations

Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature

ESMO Open2017-01-0118 citations

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).

2016-08-0819 citations